

Appendix 1

1. PubMed search strategy

('lung cancer*' OR 'lung'/exp OR lung) AND (neoplasms* OR 'non-small-cell lung carcinoma*' OR 'non small cell lung carcinoma'/exp OR 'non small cell lung carcinoma' OR 'non-small cell lung carcinoma' OR 'non-small cell lung carcinoma'/exp OR 'non-small cell lung carcinoma' OR 'non-small cell lung cancer'/exp OR 'non-small cell lung cancer' OR 'nonsmall cell lung cancer'/exp OR 'nonsmall cell lung cancer') AND ('immune checkpoint inhibitor*' OR 'immunotherapy'/exp OR immunotherapy OR 'immune checkpoint blockers' OR 'immune checkpoint blockade'/exp OR 'immune checkpoint blockade' OR 'immune checkpoint inhibition'/exp OR 'immune checkpoint inhibition' OR 'pd-l1 inhibitor*' OR 'pd l1 inhibitor*' OR 'programmed death-ligand 1 inhibitor*' OR 'programmed death ligand 1 inhibitor*' OR 'ctla-4 inhibitor*' OR 'ctla 4 inhibitor*' OR 'cytotoxic t-lymphocyte-associated protein 4 inhibitor*' OR 'cytotoxic t lymphocyte associated protein 4 inhibitor*' OR 'pd-1 inhibitor*' OR 'pd 1 inhibitor*' OR 'programmed cell death protein 1 inhibitor'/exp OR 'programmed cell death protein 1 inhibitor' OR 'programmed cell death protein 1 inhibitors' OR 'pd-1-pd-l1 blockade' OR 'pd 1 pd l1 blockade' OR 'nivolumab'/exp OR 'nivolumab' OR 'pembrolizumab'/exp OR 'pembrolizumab' OR 'atezolizumab'/exp OR 'atezolizumab' OR 'durvalumab'/exp OR 'durvalumab') AND ('nlr' OR 'neutrophil to lymphocyte ratio'/exp OR 'neutrophil to lymphocyte ratio' OR 'neutrophil-to-lymphocyte ratio'/exp OR 'neutrophil-to-lymphocyte ratio' OR 'neutrophil-lymphocyte ratio'/exp OR 'neutrophil-lymphocyte ratio')

2. EMBASE search strategy (adapted to EMTree terms)

('lung cancer*' OR 'lung neoplasm'/exp OR 'lung carcinoma'/exp OR 'non-small cell lung carcinoma'/exp OR 'non-small cell lung cancer'/exp OR 'nonsmall cell lung cancer') AND ('immune checkpoint inhibitor*' OR 'immunotherapy'/exp OR 'immune checkpoint blockade'/exp OR 'immune checkpoint inhibition'/exp OR 'pd-l1 inhibitor*' OR 'programmed death-ligand 1 inhibitor*' OR 'ctla-4 inhibitor*' OR 'cytotoxic t-lymphocyte-associated protein 4 inhibitor*' OR 'pd-1 inhibitor*' OR 'programmed cell death protein 1 inhibitor'/exp OR 'nivolumab'/exp OR 'pembrolizumab'/exp OR 'atezolizumab'/exp OR 'durvalumab'/exp) AND ('nlr' OR 'neutrophil to lymphocyte ratio'/exp OR 'neutrophil-to-lymphocyte ratio'/exp OR 'neutrophil-lymphocyte ratio'/exp)

3. Web of Science search strategy (TS = topic search)

TS=('lung cancer*' OR 'lung neoplasm' OR 'lung carcinoma' OR 'non-small cell lung carcinoma' OR 'non-small cell lung cancer' OR 'nonsmall cell lung cancer') AND TS=('immune checkpoint inhibitor*' OR 'immunotherapy' OR 'immune checkpoint blockade' OR 'immune checkpoint inhibition' OR 'pd-l1 inhibitor*' OR 'programmed death-ligand 1 inhibitor*' OR 'ctla-4 inhibitor*' OR 'cytotoxic t-lymphocyte-associated protein 4 inhibitor*' OR 'pd-1 inhibitor*' OR 'programmed cell death protein 1 inhibitor' OR 'nivolumab' OR 'pembrolizumab' OR 'atezolizumab' OR 'durvalumab') AND TS=('nlr' OR 'neutrophil to lymphocyte ratio' OR 'neutrophil-to-lymphocyte ratio' OR 'neutrophil-lymphocyte ratio')

4. Cochrane Library search strategy

('lung cancer*' OR 'lung neoplasm' OR 'lung carcinoma' OR 'non-small cell lung carcinoma' OR 'non-small cell lung cancer' OR 'nonsmall cell lung cancer') AND ('immune checkpoint inhibitor*' OR 'immunotherapy' OR 'immune checkpoint blockade' OR 'immune checkpoint inhibition' OR 'pd-l1 inhibitor*' OR 'programmed death-ligand 1 inhibitor*' OR 'ctla-4 inhibitor*' OR 'cytotoxic t-lymphocyte-associated protein 4 inhibitor*' OR 'pd-1 inhibitor*' OR 'programmed cell death protein 1 inhibitor' OR 'nivolumab' OR 'pembrolizumab' OR 'atezolizumab' OR 'durvalumab') AND ('nlr' OR 'neutrophil to lymphocyte ratio' OR 'neutrophil-to-lymphocyte ratio' OR 'neutrophil-lymphocyte ratio')